Anti-sclerostin antibody, antigen binding fragment and medical use thereof

Patent metadata

Field	Value
Publication number	US-10449250-B2
Application number	US-201615556488-A
Country	US
Kind code	B2
Filing date	Feb 16, 2016
Priority date	Mar 13, 2015
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).

First claim

The invention claimed is:

1. An antibody or antigen-binding fragment thereof that specifically binds to human sclerostin, comprising:
(I) a heavy chain variable region comprising a heavy chain complementarity determining region 1 (CDR1), a heavy chain CDR2, and a heavy chain CDR3 having the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9, respectively; and
a light chain variable region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3 having the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, respectively; or
(II) a heavy chain variable region comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 having the amino acid sequences of SEQ ID NO: 7, SEQ ID NO: 13, and SEQ ID NO: 9, respectively; and
a light chain variable region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3 having the amino acid sequences of SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12, respectively.

2. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 1 , wherein the antibody or the antigen-binding fragment thereof is a murine antibody or fragment thereof.

3. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 2 , wherein the heavy chain variable region sequence of the murine antibody comprises SEQ ID NO: 5, or a sequence having at least 95% identity to SEQ ID NO: 5.

4. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 2 , wherein the light chain variable region sequence of the murine antibody comprises SEQ ID NO: 6, or a sequence having at least 95% identity to SEQ ID NO: 6.

5. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 1 , wherein the antibody or the antigen-binding fragment thereof is a chimeric antibody or humanized antibody, or a fragment thereof.

6. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 5 being a humanized antibody, wherein the humanized antibody comprises framework regions FR1, FR2, FR3, and FR4 of human germline heavy chain IGHV1-18*01, or a mutant sequence thereof.

7. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 6 , wherein the humanized antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 14-16, a mutant sequence thereof, and sequences having at least 95% identity to SEQ ID NOs: 14-16.

8. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 5 being a humanized antibody, wherein the humanized antibody comprises framework regions FR1, FR2, FR3, and FR4 of human germline light chain IGK V1-39*01 or IGK V4-1*01, or a mutant sequence thereof.

9. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 8 , wherein the humanized antibody comprises a light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NOs: 17-19, a mutant sequence thereof, and sequences having at least 95% identity to SEQ ID NOs: 17-19.

10. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 5 being a humanized antibody, wherein the humanized antibody comprises:
a heavy chain variable region sequence of SEQ ID NO: 14 and a light chain variable region sequence of SEQ ID NO: 17;
a heavy chain variable region sequence of SEQ ID NO: 15 and a light chain variable region sequence of SEQ ID NO: 18; or
a heavy chain variable region sequence of SEQ ID NO: 16 and a light chain variable region sequence of SEQ ID NO: 19.

11. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 5 , wherein the heavy chain constant region of the humanized antibody comprises a constant region derived from human IgG1 or a variant thereof, human IgG2 or a variant thereof, human IgG3 or a variant thereof, or human IgG4 or a variant thereof.

12. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 11 , comprising a full-length heavy chain sequence selected from the group consisting of SEQ ID NOs: 24-26 and sequences having at least 90% identity to SEQ ID NOs: 24-26.

13. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 5 , wherein the light chain constant region of the humanized antibody comprises a constant region selected from the group consisting of human κ and human λ, or a variant thereof.

14. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 13 , comprising a full-length light chain sequence selected from the group consisting of SEQ ID NOs: 27-29 and sequences having at least 90% identity to SEQ ID NOs: 27-29.

15. The antibody or antigen-binding fragment thereof that specifically binds to human sclerostin according to claim 5 , comprising:
a full-length heavy chain sequence of SEQ ID NO: 24 and a full-length light chain sequence of SEQ ID NO: 27;
a full-length heavy chain sequence of SEQ ID NO: 25 and a full-length light chain sequence of SEQ ID NO: 28; or
a full-length heavy chain sequence of SEQ ID NO: 26 and a full-length light chain sequence of SEQ ID NO: 29.

16. A pharmaceutical composition, comprising the antibody or antigen-binding fragment thereof according to claim 1 , and one or more pharmaceutically acceptable excipients, diluents or carriers.

17. A pharmaceutical composition, comprising the antibody or antigen-binding fragment thereof according to claim 15 , and one or more pharmaceutically acceptable excipients, diluents or carriers.

18. A method of increasing at least one of bone mass, bone mineral density, bone mineral content, and bone strength in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition according to claim 16 .

19. A method of treating a sclerostin (SOST)-mediated bone disease or disorder in a subject in need thereof, the method comprising administering to the subject the pharmaceutical composition according to claim 16 , wherein the SOST-mediated bone disease or disorder is selected from the group consisting of osteoporosis, osteopenia, osteoarthritis, rheumatoid arthritis, periodontal disease, and multiple myeloma.

20. A method of increasing at least one of bone mass, bone mineral density, bone mineral content, and bone strength in a subject in need thereof, or a method of treating a sclerostin (SOST)-mediated bone disease or disorder in a subject in need thereof, wherein the SOST-mediated bone disease or disorder is selected from the group consisting of osteoporosis, osteopenia or osteoarthritis, rheumatoid arthritis, periodontal disease, and multiple myeloma, the method comprising administering to the subject the pharmaceutical composition according to claim 17 .

Assignees

• Jiangsu Hengrui Medicine Co
• Shanghai hengrui pharmaceutical co ltd

Inventors

• Liu Jiajian
• Fu Yayuan
• Zhang Haoying
• Wang Yifang
• Zhang Zhen
• Zhang Ling
• Cui Dongbing
• Zhang Lianshan
• Tao Weikang

Classifications

• C12N15/63

  Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• A61P19/10 Primary

  for osteoporosis · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P1/02

  Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis · CPC title